ASK

亜型選択性的な製品

ASK製品

  • All (4)
  • ASK阻害剤 (4)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S8292 Selonsertib (GS-4997) Selonsertib (GS-4997) is a highly selective and potent once-daily oral ASK1 inhibitor with potential anti-inflammatory, antineoplastic and anti-fibrotic activities.
Cell Death Dis, 2023, 14(7):467
Cell Death Dis, 2023, 14(7):467
Exp Mol Med, 2022, 54(9):1511-1523
S8289 NQDI-1 NQDI 1, an inhibitor of ASK1(apoptosis signal-regulating kinase 1), attenuates acute ischemic renal injury by modulating oxidative stress and cell death.
Redox Biol, 2023, 60:102618
J Neuroinflammation, 2023, 20(1):22
Mol Med Rep, 2023, 27(2)47
S0067 GS-444217 GS-444217 (ASK1-IN-1) is a potent, selective, orally available and ATP-competitive inhibitor of ASK1 (apoptosis signal-regulating kinase 1) with IC50 of 2.87 nM.
E2379 ASK1-IN-2 ASK1-IN-2 is a potent and orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with an IC50 of 32.8 nM.
S8292 Selonsertib (GS-4997) Selonsertib (GS-4997) is a highly selective and potent once-daily oral ASK1 inhibitor with potential anti-inflammatory, antineoplastic and anti-fibrotic activities.
Cell Death Dis, 2023, 14(7):467
Cell Death Dis, 2023, 14(7):467
Exp Mol Med, 2022, 54(9):1511-1523
S8289 NQDI-1 NQDI 1, an inhibitor of ASK1(apoptosis signal-regulating kinase 1), attenuates acute ischemic renal injury by modulating oxidative stress and cell death.
Redox Biol, 2023, 60:102618
J Neuroinflammation, 2023, 20(1):22
Mol Med Rep, 2023, 27(2)47
S0067 GS-444217 GS-444217 (ASK1-IN-1) is a potent, selective, orally available and ATP-competitive inhibitor of ASK1 (apoptosis signal-regulating kinase 1) with IC50 of 2.87 nM.
E2379 ASK1-IN-2 ASK1-IN-2 is a potent and orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with an IC50 of 32.8 nM.

ASK阻害剤の選択性比較

Tags: ASK inhibition | ASK cancer | ASK activation | ASK target | ASK tumor | ASK phosphorylation | ASK activity | ASK inhibitor drugs | ASK kinase assay | ASK inhibitor cancer | ASK inhibitor therapy | ASK signaling pathway | ASK inhibitor review